Roth Positive on Cytokinetics (CYTK) Following Phase III VITALITY-ALS Initiation

July 14, 2015 10:50 AM EDT
Get Alerts CYTK Hot Sheet
Price: $33.61 -0.68%

Rating Summary:
    13 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 9 | Down: 0 | New: 19
Trade Now! 
Join SI Premium – FREE

Roth Capital affirms Cytokinetics (Nasdaq: CYTK) with a Buy rating and $18 price target following news that the company initiated the Phase III VITALITY-ALS study.

Analyst Joseph Pantginis offered the following commentary on the event: We believe the initiation of this Phase III study highlights CYTK's successful management of the outcome of BENEFIT-ALS which was initially perceived as another failure in ALS but with additional work and analyses showed that tirasemtiv was the first ALS treatment to show a positive clinical on respiratory function. With regards to the study design we believe that the company has learned valuable lessons from BENEFIT-ALS, implementing necessary changes into the protocol.

For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, FDA

Related Entities

Roth Capital